Flawless balance sheet, good value and pays a dividend
PHH2 is financially robust, with ample cash on hand and short-term investments to meet upcoming liabilities. This implies that PHH2 manages its cash and cost levels well, which is a key determinant of the company’s health. PHH2 seems to have put its debt to good use, generating operating cash levels of 5.24x total debt in the most recent year. This is also a good indication as to whether debt is properly covered by the company’s cash flows. PHH2's share price is trading at below its true value, meaning that the market sentiment for the stock is currently bearish. This mispricing gives investors the opportunity to buy into the stock at a cheap price compared to the value they will be receiving, should analysts' consensus forecast growth be correct. Also, relative to the rest of its peers with similar levels of earnings, PHH2's share price is trading below the group's average. This supports the theory that PHH2 is potentially underpriced.

For those seeking income streams from their portfolio, PHH2 is a robust dividend payer as well. Over the past decade, the company has consistently increased its dividend payout, reaching a yield of 2.10%.

Next Steps:
For Paul Hartmann, I've compiled three key factors you should further research:
- Future Outlook: What are well-informed industry analysts predicting for PHH2’s future growth? Take a look at our free research report of analyst consensus for PHH2’s outlook.
- Historical Performance: What has PHH2's returns been like over the past? Go into more detail in the past track record analysis and take a look at the free visual representations of our analysis for more clarity.
- Other Attractive Alternatives : Are there other well-rounded stocks you could be holding instead of PHH2? Explore our interactive list of stocks with large potential to get an idea of what else is out there you may be missing!
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
Simply Wall St analyst Simply Wall St and Simply Wall St have no position in any of the companies mentioned. This article is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
About DB:PHH2
Paul Hartmann
Manufactures and sells medical and care products in Germany, rest of Europe, the Middle East, Africa, Asia and Pacific region, and the Americas.
Excellent balance sheet established dividend payer.
Similar Companies
Market Insights
Community Narratives


